Miglitol
Glyset (miglitol) is a small molecule pharmaceutical. Miglitol was first approved as Glyset on 1996-12-18. It is used to treat type 2 diabetes mellitus in the USA. The pharmaceutical is active against lysosomal alpha-glucosidase and maltase-glucoamylase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Glyset (generic drugs available since 2015-02-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Miglitol
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GLYSET | Mylan | N-020682 RX | 1996-12-18 | 3 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
miglitol | ANDA | 2022-04-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
165 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Induced abortion | D000028 | — | 1 | 1 | 2 | 12 | 16 | ||
Leiomyoma | D007889 | HP_0000131 | D25 | 1 | 5 | 4 | 1 | — | 8 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 2 | — | 2 | 1 | 6 |
Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | — | 3 | 1 | 2 | 6 |
Fetal death | D005313 | HP_0003826 | — | — | 1 | 2 | 1 | 4 | |
Missed abortion | D000030 | O02.1 | — | — | — | 4 | — | 4 | |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | 1 | — | 1 | — | 3 |
Pregnancy rate | D018873 | — | — | — | 3 | — | 3 | ||
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | 1 | 1 | 2 |
Pregnancy complications | D011248 | — | — | — | 2 | — | 2 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | 6 | — | — | 7 |
Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | 1 | 4 | — | — | 5 |
Psychotic disorders | D011618 | F20.81 | — | 1 | 5 | — | — | 5 | |
Male breast neoplasms | D018567 | 2 | — | 1 | — | — | 3 | ||
Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | 1 | 1 | — | — | 2 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 2 | — | — | 2 |
Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | 1 | — | — | 1 |
Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 1 | — | — | 1 |
Cocaine-related disorders | D019970 | F14 | — | 1 | 1 | — | — | 1 | |
Psychotic affective disorders | D000341 | F39 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 2 | — | — | 1 | 7 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 3 | — | — | 1 | 4 |
Prostatic neoplasms | D011471 | C61 | 2 | 2 | — | — | — | 3 | |
Triple negative breast neoplasms | D064726 | — | 1 | — | — | 1 | 2 | ||
Non-small-cell lung carcinoma | D002289 | 1 | 1 | — | — | — | 2 | ||
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | — | — | 2 |
Fallopian tube neoplasms | D005185 | 1 | 1 | — | — | — | 2 | ||
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 2 | — | — | — | 2 |
Hepatitis b | D006509 | — | 1 | — | — | — | 1 | ||
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
Depression | D003863 | F33.9 | 1 | — | — | — | 2 | 3 | |
Ovarian epithelial carcinoma | D000077216 | 2 | — | — | — | — | 2 | ||
Persian gulf syndrome | D018923 | EFO_0007430 | 1 | — | — | — | — | 1 | |
Occupational diseases | D009784 | 1 | — | — | — | — | 1 | ||
Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
Transitional cell carcinoma | D002295 | 1 | — | — | — | — | 1 | ||
Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
Tobacco use disorder | D014029 | F17 | 1 | — | — | — | — | 1 | |
Intraductal carcinoma noninfiltrating | D002285 | D05.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Incomplete abortion | D000027 | EFO_1001799 | — | — | — | — | 2 | 2 | |
Neoplasms | D009369 | C80 | — | — | — | — | 1 | 1 | |
Postcoital contraception | D044363 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MIGLITOL |
INN | miglitol |
Description | Miglitol is a member of piperidines. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO |
Identifiers
PDB | 3L4W |
CAS-ID | 72432-03-2 |
RxCUI | 30009 |
ChEMBL ID | CHEMBL1561 |
ChEBI ID | 6935 |
PubChem CID | 441314 |
DrugBank | DB00491 |
UNII ID | 0V5436JAQW (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,636 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
6,430 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more